Introduction: This study aimed to analyse the concordance rate, sensitivity, specificity,
INTRODUCTION
Breast cancer is the most common cancer affecting women in Singapore; about 1,600 new cases are detected annually. (1) Although the incidence of breast cancer in Singapore is increasing at an average rate of 5% annually, the global mortality rates for breast cancer have significantly decreased since the 1970s and survival rates have increased; this is probably due to better screening, early detection and improved treatment. (2, 3) Core needle biopsy (CNB) has been well established as an important tool in cancer diagnosis. It is commonly performed before the start of any treatment. CNB is considered the method of choice for tissue sampling that is a part of triple assessment. CNB is accurate in diagnosing breast carcinoma, with a specificity ranging from 96% to 100%. (4) Molecular profiling of cancer, an important aspect in cancer treatment, is also determined using CNB.
Profiling includes ascertaining the levels of oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (Her2neu) in the cancer. The molecular profile of breast cancer is critical in the management of patients with breast carcinoma. ER level is a powerful predictive factor for response to endocrine treatment and long-term outcome. (5) On the other hand, Her2neu overexpression has been associated with worse prognosis; it is also a predictor of response to trastuzumab and/or pertuzumab treatment. (6) Surgical specimen (SS) has traditionally been the gold standard in the assessment of predictive and prognostic factors for breast cancer. The results obtained from CNB may be ambiguous and not representative of the whole tumour as the distribution of antigens could be varied within the tumour (i.e. tumour heterogeneity) and the sample obtained is small. Other than that, CNB is also prone to crush or edge artefacts. A recent meta-analysis, however,
showed that CNB could replace SS in the determination of ER, PgR and Her2neu status.
The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) has estimated that 20% of overall ER testing might be inaccurate due to variability in postanalytical processes. (8) Based on this finding, it recommended in June 2010 that testing reliability be increased by lowering the positivity threshold of both ER and PgR positive cells from 10% to 1%. (8) The purpose of the present study was twofold: (a) to deduce the concordance rate between CNB and SS for ER, PgR and Her2neu status; and (b) to compare the specificity and sensitivity of the old and new thresholds for determining ER and PgR status. (9, 10) In the present study, the ER, PgR and Her2neu status of the breast cancers were determined using IHC. Paraffin sections of the tissues were fixed for 6-48 hours with 10% neutral buffered formalin. These sections were then stained and studied for the  ER and PgR status was considered to be negative, if < 1% of the tumour nuclei were immunoreactive, even in the presence of positive internal epithelial elements.
METHODS
 ER and PgR status was considered to be uninterpretable, if no tumour nuclei were immunoreactive and the internal epithelial elements lack nuclear staining.
Her2neu status interpretation was done according to ASCO/CAP 2010 guidelines.
The concordance, sensitivity, specificity, negative predicative value (NPV) and positive predicative value (PPV) were calculated by using CNB as the test assessment and SS as the gold standard. Exact 95% confidence intervals were calculated based on the binomial distribution.
RESULTS
The clinicopathological characteristics of the 560 patients that were treated in our hospital are summarised in Table I . Group 2, which consisted of patients who had their ER and PgR data collected from January 2011 to December 2012 (i.e. after the revised ASCO/CAP guidelines had been implemented).
There were 286 patient samples for ER in Group 1 and 264 patient samples for ER in Group 2 (Table II) . Among the patient samples, 75.9% were found to be ER positive in Group 1, while 74.6% were found to be ER positive in Group 2 (Table III) . The diagnostic statistics for ER status are shown in Table III .
When the ER status of Group 1 was compared with the ER status of Group 2, the specificity and PPV were found to have increased (from 79.2% to 92.5% and from 93.9% to 97.5%, respectively). In other words, the evaluation of ER-positive patients became easier after the revised ASCO/CAP guidelines (i.e. ASCO/CAP 2010) were implemented in our hospital.
There were 22 patients with discordant results between CNB and SS in Group 1 (i.e. the concordance rate was 94.8%). CNB was found to be better than SS in predicting ER positivity in the present study -19 SS that were reported as ER negative were ER positive in CNB, while only three CNB samples reported as ER negative turned out to be ER positive in SS. The concordance rate between CNB and SS was higher in Group 2 than in Group 1 (97.4% vs.
94.8%). CNB was found to be more reliable than SS in predicting the ER positivity after the change in guidelines. 
DISCUSSION
Breast conservation surgery is becoming increasingly popular among women with breast cancer. To that end, many patients opt for neoadjuvant chemotherapy to shrink the size of the tumour, as this would facilitate breast conservation surgery. Accurate determination of the molecular profile of the tumour is important to predict which patient groups would benefit the most from neoadjuvant chemotherapy.
Although SS has traditionally been considered the gold standard for molecular profiling, ASCO and CAP jointly recommend the preferential use of CNB samples for ER and PgR testing; this recommendation is based on their empiric observations that CNB samples are more likely to fix better in formalin than SS samples. (11) For SS, the time from the interruption of the blood supply to the initiation of fixation is longer. The resected specimens are not immediately sliced and fixed, resulting in poor fixation of the tumour. In our hospital, fixation protocols are more standardised for CNB than for SS; the samples obtained from CNB are fixed in formalin immediately for analysis in the lab, while the time from resection to fixation is usually much longer for surgically excised specimens. It is known that preanalytical variables such as prolonged time to fixation, surface fixation, or prolonged fixation in neutral buffered formalin can lead to negative ER/PgR results. In the present study, we did not analyse the fixation time as there is variable time delay at the different stages of specimen preparation (e.g. marking the specimen, weighing the specimen, taking photographs of the specimen and transportation of the specimen for imaging); there is also a lack of data from KK Women's and
Children's Hospital's database on fixation time. (12) (13) (14) (15) (16) There are, however, disadvantages associated with the use of CNB samples for molecular profiling. Previous studies have reported that there is a tendency towards upscoring in CNB as compared to SS; this finding is probably due to the better fixation that is achieved with CNB as compared to SS. (17) CNB samples are also prone to crush artefacts, which may lead to false positive results. Other than that, CNB may not accurately reflect the biological profile of the tumour, as sampling error may occur due to the heterogeneous distribution of the antigens within the tumour.
Previous studies have shown variable concordance rates between CNB and SS; the rates range from 61% to 99% for ER, from 61% to 91% for PgR and from 64% to 96% for Her2neu. (18) In the present study, concordance rate between CNB and SS for ER and Her2neu
were high (96.1% and 96.8%, respectively); for PgR, the concordance rate was only 89.1%.
The overall rate of PgR positivity was 75.3%.
Our analysis of the discordant results for ER showed that 22 patients had discordant results in Group 1 (i.e. the group that was scored based on the old ASCO/CAP guidelines).
CNB was found to be better than SS at predicting ER positivity, and this can likely be attributed to the better processing and fixation associated with CNB. In the present study, about 3.4% of patients would have benefited from endocrine therapy because of the higher specificity of CNB; these patients would have missed the benefit if only SS results were used for therapy decisions. If the ER status is negative on CNB, it should be repeated in the subsequent SS to confirm ER negativity.
The discordant results between CNB and SS for ER status was reduced by > 50% (from 15 to 7) after the revised ASCO/CAP guidelines were implemented. The revised ASCO/CAP guidelines, which changed the threshold for determining ER status, resulted in increased PPV, NPV and specificity. In other words, it made CNB more accurate and reliable for predicting ER status.
Probable explanations for the discordant findings include tumour heterogeneity, variation in tissue processing and fixation, inter-and intraobserver variability, sampling error, and delay in the exposure of the centre of SS sample to formalin; all of these could have resulted in false negative results. Douglas-Jones et al noted that 35% lower staining was seen in SS as compared to CNB when tissue assay was done on the same specimen. (19) Immunoreactivity for both ER and PgR was significantly higher in CNB than in SS. Douglas-Jones et al also noted that the periphery of the tumours generally stained more intensely than the centre in SS. This variation was not seen in CNB, suggesting that such findings may be an artefact problem in SS. (19) Formalin fixation induces the formation of crosslinks between proteins and nucleic acids, and this is necessary for IHC analysis. Irregular and/or inadequate formalin fixation, due to delayed fixation, under-fixation or over-fixation, can reduce the reliability of IHC staining.
In the present study, the overall concordance between CNB and SS for PgR status was 89.1%. There was a total of 60 patients with discordant PgR results in the two groups -29
PgR-positive tumours in CNB turned out to be PgR negative in SS histology and 31 tumours that were PgR negative in CNB turned out to be PgR positive in SS. Hence, CNB can miss 5.6% of PgR-positive patients if the PgR study is done using CNB only. Although consideration for endocrine treatment is generally not based on PgR status alone, PgR expression is still used as a prognostic index. (20, 21) In most previous studies, as well as in the present study, the concordance between CNB and SS for PgR is relatively low and hence the results obtained need to be used with caution.
The higher discordance rate seen for PgR status as compared to ER status might be due to the higher tumour heterogeneity for PgR. As the expression of PgR is often dependent on an intact signal pathway and the histological grade of the tumour, PgR frequently shows a more heterogeneous spread within the tumour cells. (22) It is thought that poorly differentiated tumours are more often PgR negative, and that if a tumour is PgR positive, it will not be easily influenced by external signals. (22) In the present study, the number of discordant results for PgR was reduced from 33 to 27 (i.e. a 19% reduction in discordant rate) after the revised ASCO/CAP guidelines were implemented. There was only a marginal increase in the specificity, PPV and concordance rates for PgR after the revised ASCO/CAP guidelines were implemented.
The concordance between CNB and SS for Her2neu was 96.8% in the present study. To improve CNB accuracy further, some studies have suggested that a minimum of five samples be taken (instead of a maximum of five samples) and that samples should be taken from the centre and periphery of the tumour. (23) Using tissue microarray analysis to overcome tumour heterogeneity problems may also improve CNB results further.
In the present study, the concordance between CNB and SS is high for ER and Her2neu
(96.1% and 96.8%, respectively). However, for PgR, it was only 89.1%. As the concordance for PgR is not high, caution needs to be exercised when interpreting CNB PgR results. The discordant results for ER were reduced by > 50% after the revised ASCO/CAP guidelines were implemented, while the discordant results for PgR decreased by 19% after the implementation of the revised ASCO/CAP guidelines. In other words, the revised ASCO/CAP guidelines have made the interpretation of CNB results more accurate and reliable in predicting both ER and PgR status. Since about 75% of breast cancers are hormone-receptor positive, the ability to avoid a repeat hormonal study in SS will reduce the cost of medical expenditure to both the patient and the hospital.
To conclude, the present study provides evidence that: (a) CNB is accurate for the evaluation of the molecular profile of invasive breast cancer, especially ER and Her2neu status;
and (b) the evaluation of the molecular profile of the cancer does not need be repeated on SS except in cases where CNB is negative for ER, PgR or Her2neu and in cases where the cancer is shown to be weakly positive. Repeat tests are done on SS in such cases to prevent patients from missing out on the potential benefits of targeted therapy.
